Accessibility Menu
Natera Stock Quote

Natera (NASDAQ: NTRA)

$186.74
(-1.0%)
-1.86
Price as of October 21, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$186.88
Daily Change
(-1.0%) $1.86
Day's Range
$185.65 - $190.2
Previous Close
$186.88
Open
$187.95
Beta
1.48
Volume
782,416
Average Volume
1,277,896
Market Cap
25.9B
Market Cap / Employee
$188.60M
52wk Range
$117.27 - $196.63
Revenue
-
Gross Margin
0.63%
Dividend Yield
N/A
EPS
-$1.9
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Natera Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
NTRA+54.08%+177.39%+22.64%+729%
S&P+14.84%+96.04%+14.41%+224%

Natera Company Info

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$546.60M32.2%
Gross Profit$346.60M42.5%
Gross Margin63.41%4.6%
Market Cap$23.07B73.5%
Market Cap / Employee$5.20M0.0%
Employees4.4K34.6%
Net Income-$100.94M-169.4%
EBITDA-$100.51M-179.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$1.00B25.5%
Accounts Receivable$309.22M-8.0%
Inventory54.332.4%

Liabilities

Q2 2025YOY Change
Long Term Debt$102.74M-70.2%
Short Term Debt$93.39M0.7%

Ratios

Q2 2025YOY Change
Return On Assets-15.47%5.7%
Return On Invested Capital-37.00%3.6%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$11.68M251.9%
Operating Free Cash Flow$37.57M841.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book17.9422.3715.6918.5211.13%
Price to Sales10.2612.2610.4111.7319.96%
Price to Tangible Book Value17.9422.3715.6918.5211.13%
Price to Free Cash Flow TTM300.41223.67220.37-
Enterprise Value to EBITDA-490.29-351.53-261.07-221.08-38.11%
Free Cash Flow Yield0.3%0.4%0.5%-
Return on Equity-25.8%-19.4%-18.7%-24.3%-40.37%
Total Debt$475.73M$187.12M$195.60M$196.14M-55.18%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.